ULTRALIFE CORP
No SEC Form 4 filings for $ULBI in the last 30 days.
Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.
ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1001163.htm EXHIBIT 99.1 ex_1001163.htm Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following re
Ultralife Corporation (NASDAQ: ULBI) reported Q2 2026 results for the quarter ended June 30. Sales fell to $47.9 million from $48.6 million in Q2 2025. Gross profit rose to $13.9 million, with gross margin 28.9%. GAAP EPS was $0.15 vs $0.05, and adjusted EBITDA was $6.1 million vs $4.1 million. Backlog rose to $117.5 million.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ULBI (ULTRALIFE CORP). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ULBI coverage spans financial news, earnings and corporate actions.
Margin expansion and record backlog are the key near-term drivers, with additional demand and shipment timing discussed for communications and wearable batteries.
Margin expansion and higher adjusted EBITDA suggest improving profitability, but revenue is slightly down and operating expenses rose with product development and litigation-related costs.
Margin expansion and record backlog support a constructive near-term earnings outlook, but revenue is slightly down YoY.
The 8-K discloses routine shareholder voting outcomes with no new financial guidance or corporate action beyond governance items.
Insider buying supports a modest bullish read-through, but it follows a recent earnings miss and small-cap liquidity can amplify noise.
alphai scores every news story that mentions ULBI with an AI model for sentiment and relevance, and aggregates insider trades from ULTRALIFE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.
6 min readULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1001163.htm EXHIBIT 99.1 ex_1001163.htm Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following re
6 min readUltralife Corporation (NASDAQ: ULBI) reported Q2 2026 results for the quarter ended June 30. Sales fell to $47.9 million from $48.6 million in Q2 2025. Gross profit rose to $13.9 million, with gross margin 28.9%. GAAP EPS was $0.15 vs $0.05, and adjusted EBITDA was $6.1 million vs $4.1 million. Backlog rose to $117.5 million.
4 min readULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ulbi20260723_8k.htm false 0000875657 0000875657 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 23, 2026 Date of Report (Date of Earli
1 min readUltralife (NASDAQ:ULBI) director Bradford Whitmore bought 67,302 shares on May 26 at an average $6.81, for $458,326.62, according to an SEC filing. Post-trade, he owned 2,050,637 shares (~$13.96M). The stock trades near $7.76. On May 8, Ultralife reported Q results of -$0.03 EPS and $47.45M revenue, below consensus.
4 min readWHITMORE BRADFORD T purchased 32,876 indirectly-held shares of ULTRALIFE CORP (ULBI) at $6.13 ($0.20M total) on 2026-05-21.
1 min readThis page provides a comprehensive resource for Ultralife (ULBI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It highlights recent filings, such as a Form 4 detailing insider purchases by director Bradford T. Whitmore, and provides information on Ultralife's financial performance and corporate governance. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
5 min readUltralife Corp. reported a Q4 fiscal loss of $7.4 million, or 45 cents per share, though adjusted earnings were 12 cents per share. Quarterly revenue reached $48.5 million. For the entire fiscal year, the company posted an annual loss of $5.9 million, or 35 cents per share, with total annual revenue at $191.2 million.
3 min readUltralife Corp. (ULBI) reported a fourth-quarter loss of $7.4 million, or 45 cents per share. After adjusting for asset impairment costs, the company's earnings were 12 cents per share, with revenue reaching $48.5 million for the period. For the entire year, Ultralife recorded a loss of $5.9 million, or 35 cents per share, on revenues of $191.2 million.
3 min readNEWARK, N.Y., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Ultralife Corporation ( NASDAQ: ULBI ) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025.
2 min read
